These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

410 related items for PubMed ID: 32449811

  • 1. Docetaxel suppresses immunotherapy efficacy of natural killer cells toward castration-resistant prostate cancer cells via altering androgen receptor-lectin-like transcript 1 signals.
    Tang M, Gao S, Zhang L, Liu B, Li J, Wang Z, Zhang W.
    Prostate; 2020 Jul; 80(10):742-752. PubMed ID: 32449811
    [Abstract] [Full Text] [Related]

  • 2. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
    Shi L, Lin H, Li G, Sun Y, Shen J, Xu J, Lin C, Yeh S, Cai X, Chang C.
    Cancer Lett; 2016 Apr 01; 373(1):45-56. PubMed ID: 26805759
    [Abstract] [Full Text] [Related]

  • 3. Targeting the androgen receptor (AR) with AR degradation enhancer ASC-J9® led to increase docetaxel sensitivity via suppressing the p21 expression.
    Luo J, Tian J, Chou F, Lin C, Xing EZ, Zuo L, Niu Y, Yeh S, Chang C.
    Cancer Lett; 2019 Mar 01; 444():35-44. PubMed ID: 30248372
    [Abstract] [Full Text] [Related]

  • 4. Overexpression of LLT1 (OCIL, CLEC2D) on prostate cancer cells inhibits NK cell-mediated killing through LLT1-NKRP1A (CD161) interaction.
    Mathew SO, Chaudhary P, Powers SB, Vishwanatha JK, Mathew PA.
    Oncotarget; 2016 Oct 18; 7(42):68650-68661. PubMed ID: 27626681
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Androgen receptor (AR) degradation enhancer ASC-J9® in an FDA-approved formulated solution suppresses castration resistant prostate cancer cell growth.
    Cheng MA, Chou FJ, Wang K, Yang R, Ding J, Zhang Q, Li G, Yeh S, Xu D, Chang C.
    Cancer Lett; 2018 Mar 28; 417():182-191. PubMed ID: 29203251
    [Abstract] [Full Text] [Related]

  • 7. ASC-J9(®) suppresses castration resistant prostate cancer progression via degrading the enzalutamide-induced androgen receptor mutant AR-F876L.
    Wang R, Lin W, Lin C, Li L, Sun Y, Chang C.
    Cancer Lett; 2016 Aug 28; 379(1):154-60. PubMed ID: 27233475
    [Abstract] [Full Text] [Related]

  • 8. Combination treatment with docetaxel and histone deacetylase inhibitors downregulates androgen receptor signaling in castration-resistant prostate cancer.
    Park SE, Kim HG, Kim DE, Jung YJ, Kim Y, Jeong SY, Choi EK, Hwang JJ, Kim CS.
    Invest New Drugs; 2018 Apr 28; 36(2):195-205. PubMed ID: 29110173
    [Abstract] [Full Text] [Related]

  • 9. Androgen receptor negatively regulates mitotic checkpoint signaling to induce docetaxel resistance in castration-resistant prostate cancer.
    Pilling A, Kim SH, Hwang C.
    Prostate; 2022 Feb 28; 82(2):182-192. PubMed ID: 34672379
    [Abstract] [Full Text] [Related]

  • 10. Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
    Mout L, Moll JM, Chen M, de Morrée ES, de Ridder CMA, Gibson A, Stuurman D, Aghai A, Erkens-Schulze S, Mathijssen RHJ, Sparreboom A, de Wit R, Lolkema MP, van Weerden WM.
    Br J Cancer; 2020 Dec 28; 123(12):1715-1719. PubMed ID: 32989230
    [Abstract] [Full Text] [Related]

  • 11. Calpain and AR-V7: Two potential therapeutic targets to overcome acquired docetaxel resistance in castration-resistant prostate cancer cells.
    Liu L, Lou N, Li X, Xu G, Ruan H, Xiao W, Qiu B, Bao L, Yuan C, Huang X, Wang K, Cao Q, Chen K, Yang H, Zhang X.
    Oncol Rep; 2017 Jun 28; 37(6):3651-3659. PubMed ID: 28498452
    [Abstract] [Full Text] [Related]

  • 12. Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.
    Komura K, Jeong SH, Hinohara K, Qu F, Wang X, Hiraki M, Azuma H, Lee GS, Kantoff PW, Sweeney CJ.
    Proc Natl Acad Sci U S A; 2016 May 31; 113(22):6259-64. PubMed ID: 27185910
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor.
    Shiota M, Kashiwagi E, Yokomizo A, Takeuchi A, Dejima T, Song Y, Tatsugami K, Inokuchi J, Uchiumi T, Naito S.
    Prostate; 2013 Sep 31; 73(12):1336-44. PubMed ID: 23775496
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals.
    Tang M, Sun Y, Huang CP, Chen L, Liu B, You B, Wang Z, Chang C.
    Cell Death Dis; 2022 Aug 29; 13(8):746. PubMed ID: 36038573
    [Abstract] [Full Text] [Related]

  • 17. Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.
    Isharwal S, Modi S, Arora N, Uhlrich C, Giri B, Barlass U, Soubra A, Chugh R, Dehm SM, Dudeja V, Saluja A, Banerjee S, Konety B.
    Prostate; 2017 May 29; 77(6):584-596. PubMed ID: 28144973
    [Abstract] [Full Text] [Related]

  • 18. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced Prostate Cancer.
    Martin SK, Kyprianou N.
    Adv Cancer Res; 2015 May 29; 127():123-58. PubMed ID: 26093899
    [Abstract] [Full Text] [Related]

  • 19. Ferroptosis inducer erastin downregulates androgen receptor and its splice variants in castration‑resistant prostate cancer.
    Yang Y, Liu T, Hu C, Xia H, Liu W, Chen J, Wu S, Jiang Y, Xu Y, Liu W, Zhao L.
    Oncol Rep; 2021 Apr 29; 45(4):. PubMed ID: 33649848
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.